Carna Biosciences, Inc. (4572.T)
JPY 282.0
(0.0%)
JPY 282.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 472.35 Million JPY | -24.38% |
| 2022 | 624.6 Million JPY | -44.08% |
| 2021 | 1.11 Billion JPY | 10.45% |
| 2020 | 1.01 Billion JPY | -33.6% |
| 2019 | 1.52 Billion JPY | 72.56% |
| 2018 | 882.63 Million JPY | 8.64% |
| 2017 | 812.47 Million JPY | -1.75% |
| 2016 | 826.97 Million JPY | 77.04% |
| 2015 | 467.1 Million JPY | 19.4% |
| 2014 | 391.21 Million JPY | 34.39% |
| 2013 | 291.11 Million JPY | 23.3% |
| 2012 | 236.1 Million JPY | -20.88% |
| 2011 | 298.42 Million JPY | 2.65% |
| 2010 | 290.73 Million JPY | 19.82% |
| 2009 | 242.64 Million JPY | -13.83% |
| 2008 | 281.6 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 470.33 Million JPY | 25.01% |
| 2024 Q1 | 376.24 Million JPY | -20.35% |
| 2023 Q4 | 472.35 Million JPY | 25.75% |
| 2023 Q2 | 453.31 Million JPY | -17.19% |
| 2023 FY | 472.35 Million JPY | -24.38% |
| 2023 Q3 | 375.61 Million JPY | -17.14% |
| 2023 Q1 | 547.42 Million JPY | -12.36% |
| 2022 Q3 | 604.47 Million JPY | -23.7% |
| 2022 Q2 | 792.26 Million JPY | -2.73% |
| 2022 Q1 | 814.5 Million JPY | -27.08% |
| 2022 FY | 624.6 Million JPY | -44.08% |
| 2022 Q4 | 624.6 Million JPY | 3.33% |
| 2021 Q3 | 731.61 Million JPY | 29.31% |
| 2021 Q2 | 565.77 Million JPY | -16.53% |
| 2021 Q1 | 677.81 Million JPY | -32.98% |
| 2021 Q4 | 1.11 Billion JPY | 52.67% |
| 2021 FY | 1.11 Billion JPY | 10.45% |
| 2020 Q2 | 805.57 Million JPY | -24.98% |
| 2020 Q1 | 1.07 Billion JPY | -29.49% |
| 2020 FY | 1.01 Billion JPY | -33.6% |
| 2020 Q4 | 1.01 Billion JPY | 7.82% |
| 2020 Q3 | 938.02 Million JPY | 16.44% |
| 2019 FY | 1.52 Billion JPY | 72.56% |
| 2019 Q1 | 753.63 Million JPY | -14.62% |
| 2019 Q2 | 1.1 Billion JPY | 46.14% |
| 2019 Q3 | 1.64 Billion JPY | 48.95% |
| 2019 Q4 | 1.52 Billion JPY | -7.15% |
| 2018 Q3 | 933.28 Million JPY | -4.25% |
| 2018 Q4 | 882.63 Million JPY | -5.43% |
| 2018 Q2 | 974.72 Million JPY | -6.88% |
| 2018 FY | 882.63 Million JPY | 8.64% |
| 2018 Q1 | 1.04 Billion JPY | 28.84% |
| 2017 Q3 | 675.22 Million JPY | -3.82% |
| 2017 FY | 812.47 Million JPY | -1.75% |
| 2017 Q4 | 812.47 Million JPY | 20.33% |
| 2017 Q2 | 702.05 Million JPY | -3.8% |
| 2017 Q1 | 729.77 Million JPY | -11.75% |
| 2016 Q1 | 323.62 Million JPY | -30.72% |
| 2016 FY | 826.97 Million JPY | 77.04% |
| 2016 Q4 | 826.97 Million JPY | 1.25% |
| 2016 Q3 | 816.76 Million JPY | 26.55% |
| 2016 Q2 | 645.42 Million JPY | 99.44% |
| 2015 Q2 | 362.56 Million JPY | 17.31% |
| 2015 Q1 | 309.05 Million JPY | -21.0% |
| 2015 FY | 467.1 Million JPY | 19.4% |
| 2015 Q4 | 467.1 Million JPY | 13.81% |
| 2015 Q3 | 410.41 Million JPY | 13.2% |
| 2014 FY | 391.21 Million JPY | 34.39% |
| 2014 Q4 | 391.21 Million JPY | 14.02% |
| 2014 Q3 | 343.1 Million JPY | 14.69% |
| 2014 Q2 | 299.15 Million JPY | 6.3% |
| 2014 Q1 | 281.41 Million JPY | -3.33% |
| 2013 FY | 291.11 Million JPY | 23.3% |
| 2013 Q1 | 251.77 Million JPY | 6.64% |
| 2013 Q2 | 232.66 Million JPY | -7.59% |
| 2013 Q3 | 274.32 Million JPY | 17.9% |
| 2013 Q4 | 291.11 Million JPY | 6.12% |
| 2012 FY | 236.1 Million JPY | -20.88% |
| 2012 Q2 | 260.42 Million JPY | -12.1% |
| 2012 Q3 | 234.44 Million JPY | -9.98% |
| 2012 Q4 | 236.1 Million JPY | 0.71% |
| 2012 Q1 | 296.27 Million JPY | -0.72% |
| 2011 FY | 298.42 Million JPY | 2.65% |
| 2011 Q4 | 298.42 Million JPY | -2.41% |
| 2011 Q1 | 294.01 Million JPY | 1.13% |
| 2011 Q3 | 305.79 Million JPY | 6.33% |
| 2011 Q2 | 287.58 Million JPY | -2.19% |
| 2010 Q1 | 300.07 Million JPY | 23.67% |
| 2010 Q2 | 246.47 Million JPY | -17.86% |
| 2010 Q4 | 290.73 Million JPY | 10.84% |
| 2010 FY | 290.73 Million JPY | 19.82% |
| 2010 Q3 | 262.29 Million JPY | 6.42% |
| 2009 Q4 | 242.64 Million JPY | 29.55% |
| 2009 Q3 | 187.29 Million JPY | 53.08% |
| 2009 Q2 | 122.35 Million JPY | -23.91% |
| 2009 Q1 | 160.8 Million JPY | 0.0% |
| 2009 FY | 242.64 Million JPY | -13.83% |
| 2008 FY | 281.6 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 85.452% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -644.91% |
| GNI Group Ltd. | 26.34 Billion JPY | 98.207% |
| Linical Co., Ltd. | 10.3 Billion JPY | 95.416% |
| Trans Genic Inc. | 3.81 Billion JPY | 87.61% |
| MEDINET Co., Ltd. | 590.2 Million JPY | 19.968% |
| Soiken Holdings Inc. | 697.02 Million JPY | 32.233% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 84.363% |
| AnGes, Inc. | 2.78 Billion JPY | 83.066% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | 8.032% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.477% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -33.709% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 71.371% |
| CanBas Co., Ltd. | 91.98 Million JPY | -413.496% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 56.808% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 41.672% |
| Chiome Bioscience Inc. | 593.73 Million JPY | 20.443% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 88.896% |
| PeptiDream Inc. | 29.11 Billion JPY | 98.378% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | 16.619% |
| Ribomic Inc. | 155.8 Million JPY | -203.163% |
| SanBio Company Limited | 2.25 Billion JPY | 79.052% |
| Healios K.K. | 11.28 Billion JPY | 95.815% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -87.988% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -28.009% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -95.595% |
| StemRIM | 187 Million JPY | -152.596% |
| CellSource Co., Ltd. | 677.73 Million JPY | 30.304% |
| FunPep Company Limited | 189.32 Million JPY | -149.496% |
| Kringle Pharma, Inc. | 596.95 Million JPY | 20.873% |
| Stella Pharma Corporation | 1.44 Billion JPY | 67.28% |
| TMS Co., Ltd. | 97.68 Million JPY | -383.529% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -416.269% |
| Cuorips Inc. | 200.96 Million JPY | -135.048% |
| K Pharma,Inc. | 209.13 Million JPY | -125.862% |
| Takara Bio Inc. | 11.42 Billion JPY | 95.864% |
| ReproCELL Incorporated | 741.03 Million JPY | 36.257% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 48.529% |
| StemCell Institute Inc. | 3.85 Billion JPY | 87.733% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 48.003% |
| CellSeed Inc. | 301.04 Million JPY | -56.904% |